Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver.

Drug-induced liver injury: A management position paper from the Latin American Association for Study of the liver. Ann Hepatol. 2021 Feb 17;:100321 Authors: Bessone F, Hernandez N, Tagle M, Arrese M, Parana R, Mendez N, Ridruejo E, Mendizabal M, Dagher L, Contreras F, Fassio E, Pesoa M, Brahm J, Silva M Abstract Idiosyncratic drug-induced liver injury (DILI) caused by xenobiotics (drugs, herbals and dietary supplements) is an uncommon cause of liver disease presenting with a wide range of phenotypes and disease severity, acute hepatitis mimicking viral hepatitis to autoimmune hepatitis, steatosis, fibrosis or rare chronic vascular syndromes. Disease severity ranges from asymptomatic liver test abnormalities to acute liver failure. DILI has been traditionally classified in predictable or intrinsic (dose-related) or unpredictable (not dose-related) mechanisms. Few prospective studies are assessing the real prevalence and incidence of hepatotoxicity in the general population. DILI registries represent useful networks used for the study of liver toxicity, aimed at improving the understanding of causes, phenotypes, natural history, and standardized definitions of hepatotoxicity. Although most of the registries do not carry out population-based studies, they may provide important data related to the prevalence of DILI, and also may be useful to compare features from different countries. With the support of the Spanish registry of hepatotox...
Source: Annals of Hepatology - Category: Gastroenterology Tags: Ann Hepatol Source Type: research